Research Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer

Junyi Zhang, Kamran Ali, Jianwei Wang

Abstract: Colorectal cancer (CRC) is a common type of gastrointestinal tract (GIT) cancer and poses an enormous threat to human health. Current strategies for metastatic colorectal cancer (mCRC) therapy primarily focus on chemotherapy, targeted therapy, immunotherapy, and radiotherapy; however, their adverse reactions and drug resistance limit their clinical application. Advances in nanotechnology have rendered lipid nanoparticles (LNPs) a promising nanomaterial-based drug delivery system for CRC therapy. LNPs can adapt to the biological characteristics of CRC by modifying their formulation, enabling the selective delivery of drugs to cancer tissues. They overcome the limitations of traditional therapies, such as poor water solubility, nonspecific biodistribution, and limited bioavailability. Herein, we review the composition and targeting strategies of LNPs for CRC therapy. Subsequently, the applications of these nanoparticles in CRC treatment including drug delivery, thermal therapy, and nucleic acid-based gene therapy are summarized with examples provided. The last section provides a glimpse into the advantages, current limitations, and prospects of LNPs in the treatment of CRC.

Keywords: lipid nanoparticles, colorectal cancer, tumor targeting, drug delivery, nanotechnology

Introduction

Globally, colorectal cancer (CRC) is the third most frequently diagnosed malignancy and the second leading cause of cancer death. Most CRC cases arise sporadically, while approximately 35% of cases are attributed to heritable factors. It is believed that the vast majority of CRCs follow the adenoma-carcinoma sequence and serrated polyp-carcinoma sequence, largely due to genetic aberrations at the cellular level. Currently, the principal therapeutic approaches for CRC include surgical intervention, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. However, the chemotherapeutic and targeted agents currently in use are associated with substantial treatment-related toxicities. These adverse effects significantly impair patients’ quality of life, constrain dosage limits, and may even cause the termination of treatment. Consequently, there is an urgent need to devise treatment strategies that minimize the non-specific distribution of drugs and mitigate toxic side effects, thereby improving both the quality of life and prognosis of CRC patients.

In response to these challenges, colon-specific drug delivery systems (CDDS), particularly those employing nanotechnology for colon targeting, have been tailored to meet the biological characteristics and clinical demands of CRC. Among the various existing drug carriers, nanoparticles (NPs) can enhance drug stability and solubility, facilitate transmembrane transport, and extend circulation time, thereby improving both safety and efficacy. Drugs absorbed in the colon are taken up by the intestinal mucosa and subsequently enter systemic circulation via the venous or lymphatic systems. Based on the pathophysiological characteristics of the microenvironment surrounding the disease site, scientists have developed several advanced CDDSs to optimize drug delivery to the colon. These systems employ various mechanisms to control and target the release of drugs, including pH-sensitive systems (eg, pH-responsive polycarboxybetaine-...
coated LNPs), enzyme-triggered systems (eg, the enzyme-responsive drug delivery system “EUG/CAS–MSNs–COOH”), and magnetically driven systems (eg, magnetically driven spmNP and EMHV DDSs). Selective surface receptor-mediated drug delivery systems (eg, folate receptor and chemokine-targeted systems) are also employed to specifically deliver drugs to cancerous cells, bypass toxic side effects, and enhance the therapeutic index.

With the advent of nanotechnology, therapeutic lipid nanoparticles (LNPs) have been widely applied in drug delivery systems (DDSs) due to their efficiency and versatility. LNPs are lipid-based nanocarriers prepared through various methods such as lipid vesicle extrusion, rehydration, nanoprecipitation, and microfluidic mixing. One of their key components is ionizable lipids, whose structure and pKa are closely related to cytoplasmic release. However, the structure and delivery characteristics of LNPs depend on the combination of different lipids. The roles of other lipid components are also indispensable, as they influence the morphology, stability, and distribution of LNPs. For example, PEG lipids on the surface of the particles can prevent aggregation and extend circulation time in vivo. LNPs exhibit lower immunogenicity and cytotoxicity compared to polymeric and inorganic nanoparticles and can be engineered for targeted modifications. Owing to these properties, they can effectively cross physiological barriers and deliver drugs precisely to lesion sites. In fact, in intestinal disease, LNP-based DDSs have been extensively studied for their ability to target lesion sites. They minimize drug exposure to normal tissues while maintaining therapeutic concentrations at the lesion site, effectively inhibiting tumor growth. Additionally, the composition, size, and surface charge of these NPs are crucial factors that influence their accumulation in and clearance from the intestinal mucosa.

Since several well-summarized reviews on nanoparticle-based therapy for cancer already exist, we specifically focus on the advancements of LNP-based anticancer therapy in CRC treatment. Firstly, we provide a brief overview of the formulation of LNPs to demonstrate how each component contributes to their overall functionality. Subsequently, we concentrate on the tumor-targeting strategies and colorectal-specific designs of LNPs, aimed at optimizing their effectiveness in treating colorectal diseases. Lastly, we summarize recent advancements in employing LNPs for colorectal cancer therapy, particularly in nucleic acid drug treatments. We also address the current challenges in this field, offering insights into future design strategies and applications.

**Lipid Nanoparticle Delivery Systems: An Overview and Composition Analysis**

Liposomes discovered in the 1960s are considered the earliest version of LNPs. Since then, numerous liposome-based drugs have been extensively applied in medical practice. With the development of nanotechnology, the term “lipid nanoparticles” emerged in the early 1990s. To overcome the limitations of liposomes, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) were developed. Both SLNs and NLCs, comprising lipids and stabilizers, offer enhanced physical stability. Extracellular vesicles are naturally occurring LNPs with a size range of 30–150 nm, which are produced by both tumor and non-tumor host cells. These vesicles, characterized by a phospholipid bilayer structure, play a pivotal role in intercellular communication. They can alter the biological state of recipient cells by transmitting proteins, nucleic acids, and other biomolecules, thereby affecting cancer recurrence, metastasis, and immune response. LNPs can be categorized into six types based on variations in structure and drug-loading mechanisms: liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric lipid hybrid nanoparticles (PLNs), lipid drug conjugates (LDCs), and exosomes (Figure 1). Each category represents a unique facet of this versatile drug delivery system, highlighting the evolution and diversification of LNP technology in biomedical research.

LNPs are multi-component drug delivery systems generally comprising cationic lipids (CLs) or ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol (PEG) lipids (Figure 2).

**Cationic/Ionizable Lipids: Key Components Shaping LNP Structure and Function**

Cationic/ionizable lipids are fundamental components of LNPs, facilitating their self-assembly through electrostatic interactions. Historically, cationic lipids were developed for LNP assembly to interact with negatively charged nucleic acids. However, their application has been limited due to significant toxicity and diminished in vivo efficacy. To
address these issues, ionizable lipids have been developed. These lipids remain neutral under physiological conditions, but acquire a net positive charge in acidic intracellular environments due to their tertiary amine components. These characteristics largely resolve toxicity and efficacy issues associated with cationic lipids.

Currently, widely used ionizable lipids are mainly divided into five categories: unsaturated, multi-tail, polymeric, biodegradable, and branched-tail lipids. These amphiphilic small molecules consist of three primary functional domains: hydrophilic head groups, linker groups, and hydrophobic tails. The size and charge density of the head group significantly influence processes such as nucleic acid encapsulation, LNP stability, biodegradation, cellular membrane interaction, and facilitation of endosomal escape. Linker groups, which bridge the head and tail groups, play a crucial role in modulating cytotoxicity, stability, biodegradability, and the transfection efficiency of LNPs. Meanwhile, the hydrophobic tails primarily contribute to particle formation and potency, impacting aspects like ionization (critical pKa) and lipophilicity (critical LogP). Collectively, these diverse functional elements of cationic and ionizable lipids are instrumental in defining the biological characteristics of LNPs.

**Helper Lipids, Cholesterol, and Polyethylene Glycol Lipids**

In addition to cationic/ionizable lipids, LNP formulations include helper lipids, cholesterol, and PEG lipids, each playing a vital role in preserving LNP properties and functionalities. Helper lipids are mostly phospholipids, accounting for...
approximately 10–20% of the total lipids in the formulations. Despite having received less research attention compared to other components, phospholipids significantly enhance LNP stability and facilitate encapsulation and delivery.

Commonly used phospholipids in clinical practice include 1,2-distearoyl-sn-glycerol-3-phosphate choline (DSPC), 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), and 1,2-dioleoyl-sn-glycerol-3-phosphate choline (DOPC). DSPC consists of a phosphatidylcholine head and two saturated 18-carbon tails. It undergoes a phase transition from an ordered gel phase to a disordered fluid crystalline phase when the temperature exceeds its phase-transition temperature. This shift aids in the formation of a tightly packed lipid bilayer structure. The choice of helper lipids can be adapted to meet different nucleic acid loading requirements. For example, DOPE, with its unsaturated tail and net neutral charge, forms a more fluid lipid layer, promoting the fusion of lipid membranes and endosomes, and ultimately improving RNA transfection efficiency. Consequently, DOPE is often used for mRNA delivery due to its higher RNA transfection efficiency compared to DSPC. DOPE also exhibits strong interaction with liver-synthesized apolipoprotein E (ApoE). Zhang et al reported that after intravenous administration, C12-200 LNPs containing DOPE primarily accumulated in the liver, whereas C12-200 LNPs containing DSPC accumulated in the spleen, highlighting the effect of auxiliary lipids on LNP organ distribution.

Selecting phospholipids based on cell line type can enhance transfection efficiency, as demonstrated by Gretskaya et al, who found that liposomal complexes with DOPC had significantly higher transfection efficiency than those with DOPE in SW620 cells. These studies indicate the crucial role of phospholipids in the delivery efficiency of LNPs, emphasizing the importance of selecting the appropriate type of LNPs.

Cholesterol, an amphiphilic natural cell membrane constituent, serves as a helper lipid in LNPs. It is involved in the degradation of LNPs within the systemic circulation and assists in their subcellular transport. Recently, researchers have begun to focus on optimizing the formulation of LNPs. For example, Patel et al have investigated substituting cholesterol with hydroxycholesterol to enhance mRNA delivery to T cells, thereby promoting the endosomal escape of LNPs and advancing their applications in immunotherapy. The molecular structure of cholesterol derivatives augments cellular uptake and extends LNP half-life in circulation.

Polyethylene glycol (PEG) lipids provide a polymeric shell for LNPs, with lipid domains deeply embedded within the particles and PEG domains extending to the surface of the particles. PEG lipids create a hydrophilic steric barrier via
Design of Colorectal-Targeted Lipid Nanoparticles
Carrier Design for Colorectal Targeting

The treatment of colorectal cancer (CRC) has advanced significantly with the use of chemotherapy, radiotherapy, and biological agents, enhancing cancer therapeutic effectiveness. However, these treatments are associated with significant drawbacks, such as the development of drug resistance and toxicity to non-cancerous cells, which can hinder therapeutic success.\textsuperscript{77,78} The use of delivery vectors has emerged as a crucial strategy to address these challenges. An optimal delivery system should effectively encapsulate drugs, protect them from degradation, and specifically target lesion sites.\textsuperscript{79} The development of non-biodegradable NPs such as polymeric NPs, LNPs, micelles, gold NPs (AuNPs), and magnetic NPs marked a significant advancement in the targeted formulation and delivery of therapeutic agents to the affected sites in the colon and rectum.\textsuperscript{31,80–84} Researchers have used NPs as drug delivery vehicles in clinical trials for CRC treatment (Table 1). In particular, LNPs stand out as a highly promising nanomedicine delivery system owing to their excellent biodegradability, biocompatibility, straightforward structural design, and the ability to tailor their functionality to specific needs.\textsuperscript{85} Various surface modifications greatly enhance cellular uptake and targeting ability of LNPs (Figure 3). Nevertheless, the accumulation and retention of LNPs in the liver following systemic or local administration impede their application in extrahepatic organs. The heightened liver affinity of LNPs is mainly attributed to three pivotal factors. First, the distinctive anatomical and physiological features of the liver, such as discrete blood vessels and sluggish blood flow, facilitate LNP extravasation and reinforce its interaction with hepatic tissues.\textsuperscript{86} Yang et al leveraged these features to design hepatocyte nuclear factor 4 alpha (HNF4A)-mRNA LNPs for targeting hepatocytes through intravenous administration, holding promise for attenuating liver fibrosis.\textsuperscript{87} Second, endogenously synthesized ApoE from the liver adheres to the surface of LNPs, forming a protein crown known as the “Corona”. ApoE then combines with low-density lipoprotein receptor (LDLR) to facilitate endocytosis in liver cells.\textsuperscript{88,89} Lastly, the LNP-Corona complex is enriched in high-density lipoprotein (HDL), steering the preferential delivery of LNPs to the liver. Therefore, to advance the application of LNPs in CRC treatment, urgent strategies must be devised to redirect LNP delivery to extrahepatic organs, including the large intestine.\textsuperscript{88} With advancements in relevant technologies, organ, tissue, or cell-specific drug delivery using LNPs can be achieved through local administration or systemic intravenous delivery. Currently, implemented targeted local administration routes of LNPs include oral, intranasal, inhalation, rectal, and local injection routes (such as intramuscular and intratumoral injections) (Figure 1).\textsuperscript{90–92} An appropriate administration route can improve the targeting efficiency of LNPs. For example, LNPs can be readily directed to the liver due to their efficient circulation in the bloodstream, making intravenous injection an appropriate administration route for liver-targeted LNPs.

The oral colon-specific drug delivery system (OCDDS) aims to convey drugs orally directly to the colon, preventing premature drug release in the stomach, duodenum, jejunum, and ileum. Such targeted delivery mechanisms enable precise treatment of diseases like CRC and inflammatory bowel disease (IBD). The development of OCDDS must account for the unique anatomical and physiological properties of the gastrointestinal tract’s various segments, such as pH levels, enzyme activity, and microbiota composition (Figure 4).\textsuperscript{100–102} The large intestine, forming the lower segment of the human digestive tract, consists of the cecum, appendix, colon (ascending, transverse, descending, and sigmoid colons), rectum, and anal canal. It plays a crucial role in absorbing water and electrolytes from food residues, forming and temporarily storing feces, and facilitating controlled excretion.\textsuperscript{103} Drugs absorbed in the colorectum are taken up by the intestinal mucosa and then enter the systemic circulation via the venous/lymphatic system. In OCDDS, nanoparticles are formulated to withstand the harsh
<table>
<thead>
<tr>
<th>Name</th>
<th>Indication</th>
<th>Intervention/Treatment</th>
<th>Stage</th>
<th>NCT Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetuximab nanoparticles (p.o.).</td>
<td>Colon Cancer</td>
<td>Drug: Cetuximab nanoparticles</td>
<td>Phase 1 (Unknown)</td>
<td>NCT03774680</td>
</tr>
<tr>
<td>Nanoparticle Paclitaxel (i.p.).</td>
<td>Colo-rectal Cancer</td>
<td>Drug: Oral approved anticancer drug</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aguix Gadolinium-Based Nanoparticles (radiotherapy)</td>
<td>Peritoneal Neoplasms</td>
<td>Drug: nanoparticulate paclitaxel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain Metastases</td>
<td>Radiation: Stereotactic Radiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: AGuIX gadolinium-based nanoparticles</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other: Placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZD4635 (p.o).</td>
<td>Advanced Solid Malignancies</td>
<td>Drug: AZD4635</td>
<td>Phase 1 (Completed)</td>
<td>NCT02740985</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Durvalumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Abiraterone Acetate</td>
<td>Phase 2 (Recruiting)</td>
<td>NCT01437007</td>
</tr>
<tr>
<td>CALAA-01 (i.v.) <em>93–96</em></td>
<td>Cancer</td>
<td>Drug: CALAA-01</td>
<td>Phase 1 (Completed)</td>
<td>NCT0689065</td>
</tr>
<tr>
<td>TKM 080301 (hepatic intra-arterial administration) <em>97–99</em></td>
<td>Solid Tumor</td>
<td>Drug: TKM-080301</td>
<td>Phase 1 (Completed)</td>
<td>NCT01437007</td>
</tr>
<tr>
<td>9-ING-41 (i.v).</td>
<td>Primary or Secondary Liver Cancer</td>
<td>Drug: 9-ING-41</td>
<td>Phase 2 (Recruiting)</td>
<td>NCT03678883</td>
</tr>
<tr>
<td></td>
<td>Advanced Cancers</td>
<td>Drug: Gemcitabine - 21 day cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Doxorubicin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Lomustine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Carboplatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Nab paclitaxel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Paclitaxel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Gemcitabine - 28 day cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Irinotecan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nal-IRI(i.v.).</td>
<td>Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer</td>
<td>Drug: Fluourouracil</td>
<td>Phase ½ (Active, not recruiting)</td>
<td>NCT03337087</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Irinotecan Sucrosofate</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other: Laboratory Biomarker Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Leucovorin Calcium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: Rucaparib</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug: nanoparticulate paclitaxel</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Updated on 01/24/2024. All clinical trials listed in this table are based on ClinicalTrials.gov.  
**Abbreviations:** P.O., oral; i.p., intraperitoneal; i.v., intravenous; nal-IRI, liposomal irinotecan.
gastrointestinal environment, thereby protecting encapsulated drugs from extreme pH and enzymatic degradation. For example, Bajracharya et al used poly (methacrylic acid-co-methyl methacrylate) (1:2) as a surface coating to prepare E/AC-Au/MTX nanocomplexes. These nanocomplexes exhibited a remarkable entrapment efficiency of over 80% while demonstrating notable pH-response characteristics. Musa et al loaded NPs in the form of soft agglomerates, which reduced premature drug release. The in vitro release experiment showed that the 5-FU-loaded NPs sustained drug release via their response to the intracapsular sodium alginate coat, indicating their potential to achieve colon-specific targeting by oral intake.

The epithelium of the large intestine is covered by a bilayered mucus structure comprising water, electrolytes, lipids, and glycoproteins. Numerous studies indicate that NPs, varying in size, shape, composition, and surface modifications, can penetrate this mucous layer and access the intestinal epithelium through different mechanisms (Figure 5).
administration of OCDDS offers several benefits, including enhanced patient compliance, ease and convenience of use, and a reduced likelihood of acute drug reactions. However, the patient-to-patient variability and the dynamic changes in the gastrointestinal environment under physiological and pathological conditions pose challenges to the clinical translation of OCDDS. Further research is needed to uncover the impact of these factors on NPs.

**Targeting Strategies of LNPs in Colorectal Cancer**

Current nanocarrier-based targeted delivery strategies for CRC can be broadly categorized into passive targeting, active targeting, and stimulus-responsive targeting (Figure 6). These approaches ingeniously exploit the biological

![Figure 5](https:// estudio.com/fig5.png) Structure of the intestinal mucosal barrier comprising microbial, chemical, mechanical, and immune barriers, along with the mechanism of NPs across the mechanical barrier. Current uptake mechanisms of NPs across intestinal epithelium include macropinocytosis, clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis (CavME), and clathrin/caveolae-independent endocytosis (CIE). Created with BioRender.com.

![Figure 6](https:// estudio.com/fig6.png) Figure 6 A diagram of major targeting strategies of LNPs for targeting CRC. (A) LNPs passively accumulate in tumors through enhanced permeability and retention effect; (B) Ligand-decorated LNPs actively target cancer cells and tumor vasculature; (C) LNPs respond to both endogenous and exogenous stimuli and release drugs rapidly at the lesion site. Created with BioRender.com.
characteristics of tumors and the tumor microenvironment (TME) to enable precise and effective drug delivery through distinct mechanisms. This section explores the principles and applications of these strategies in CRC treatment, highlighting their role in enhancing therapeutic efficacy.

Passive Targeting
The unique pathological and physiological features of tumors and TME make passive targeting strategies widely applicable in common nanocarrier systems. Tumor tissue is characterized by enlarged gaps between vascular endothelial cells, a dense extracellular matrix (ECM), and poor internal lymphatic drainage. This scenario leads to the enhanced permeability and retention (EPR) effect, facilitating the passive accumulation of nanomedicines at tumor sites (Figure 6A). This phenomenon alters the pharmacokinetics and pharmacodynamics of the encapsulated drugs and minimizes off-target toxicity, forming the cornerstone of passive targeting. In the mid-1990s, the first-generation lipid nanoparticles, liposomal doxorubicin (Doxil®) and liposomal daunorubicin (DaunoXome®), received FDA approval. Liposomal doxorubicin is a liposomal carrier of the anthracycline chemotherapeutic agent doxorubicin (DOX). The addition of PEG-lipid conjugates extends DOX’s plasma half-life to 45 hours in humans. Similarly, liposomal daunorubicin, which carries daunorubicin (DNX), exhibits altered metabolism and distribution, leading to increased tumor accumulation and reduced systemic toxicity.

Glucan and chitosan, two naturally occurring polysaccharides, have been incorporated into various drug delivery systems due to their unique structural attributes. Incorporating a chitosan shell is a prevalent strategy to enhance the colorectal targeting of nanomedicines. This shell serves a dual purpose: it protects nanomedicines from degradation in the stomach and small intestine, and upon arrival in the colon, specific glucose hydrolases degrade the shell’s surface glucan. This degradation reveals folate residues on the nanoparticles, which then target tumor cells that overexpress folate receptors. Moreover, chitosan can improve adhesion and facilitate targeted, sustained drug release in the colon through hydrophilic and electrostatic interactions with mucin.

The rapid clearance by the reticuloendothelial system (RES) and high interstitial fluid pressure (IFP) are key challenges to the efficiency of passive targeting in nanomedicines. The former reduces the half-life of LNPs, hindering accumulation at the target site, while the latter limits drug penetration into deep tumor tissues. Thus, optimizing the formulation, size, and surface charge of LNPs is crucial to enhancing targeting efficacy. Current research focuses on developing “second-generation” nanoparticles to further refine the pharmacokinetic and pharmacodynamic characteristics of drugs, aiming to bolster the treatment of solid tumors. Selective organ targeting (SORT) represents a significant innovation in this field. Cheng et al introduced a fifth type of lipid, the SORT molecule, into LNPs, altering their internal charge to achieve targeted delivery to extrahepatic organs.

A recent study by Wang et al revealed a critical but previously underestimated barrier in NP delivery – the tumor vascular basement membrane (BM). BM is a dense, cross-linked, extracellular matrix layer beneath the endothelium, enveloping the endothelial and parietal cells of tumor blood vessels. It forms a formidable mechanical barrier with endothelial cells, which traps NPs in the subendothelial space and effectively blocks their entry into the tumor. The study revealed that local hyperthermia induces platelet aggregation and inflammation, attracting neutrophils to the NP pool. These neutrophils then move through the BM barrier and release NPs, facilitating increased NP penetration into deeper tumors. This finding underlines the need for further research and engineering strategies to overcome the BM barrier in NP-mediated drug delivery.

Active Targeting
Active targeting in nanomedicine primarily involves specific ligand modifications on nanoparticle surfaces. The ligands on the surfaces of NPs bind selectively to receptors on target cells, facilitating the delivery of drugs to specific cell types (Figure 6B). Notably, these receptors are minimally or even not expressed on normal cells but are highly or specifically present on the surfaces of cancer cells. Ligand-receptor interactions can trigger receptor-mediated endocytosis, promoting the uptake of LNPs by cancer cells. Various ligands, categorized into small molecules (folate,
sugars) and macromolecules (antibodies, peptides, proteins, ligands, oligonucleotides), have been employed for LNP surface modifications. Several colorectal-specific biomarkers have been utilized in targeted ligand design. For instance, folate receptor-α (FR-α), overexpressed in many cancer types, binds naturally with folate (FA), which is stable, low in immunogenicity, and exhibits high affinity to FR-α. This renders FA a popular choice for nanomedicine targeting. Folate-bound Poly (lactico-glycolic acid) (PLGA) NPs loaded with kaempferitrin demonstrated enhanced cytotoxicity against colorectal cancer cells. A recent study analyzing four biomarkers in colorectal cancer tissues from 280 patients via immunohistochemistry revealed increased expression of FR-α (37.1%) compared to normal tissues, along with elevated levels of carcinoembryonic antigen (CEA) (98.8%), tumor-associated glycoprotein-72 (79%), and epidermal growth factor receptor (EGFR) (32.8%) in CRC, highlighting CEA’s potential as a future LNP drug target for CRC.

CD44 is a common marker of cancer stem cells (CSCs) in colon cancer and is also highly expressed. Chondroitin sulfate (CS) is a highly sulfated glycosaminoglycan. It exhibits a high affinity for CD44, making CS-modified NPs ideal for tumor targeting.

Peptides are another common targeting ligand for LNPs, favored for their strong binding to various cell targets, cost-effectiveness, high fidelity, and ability to attach to LNPs without hindering their binding ability. Tumor homing peptides (THPs) are a class of peptides that have homing effects on tumor tissue or blood vessels. They can recognize and bind to specific receptors or markers on the surface of tumor tissue or blood vessels. Peptides PIVO-8 (sequence: SNMPFSKPYGLTV) and PIVO-24 (sequence: YPHYSLPGSSTL) functionalized liposomes inhibit tumor angiogenesis and increase apoptosis in colon HCT116 tumors in mice. Fluorescence images revealed that these PIVO-targeting liposomes significantly increase drug uptake by tumor vasculature endothelial cells via receptor-mediated endocytosis. These results suggest that LNPs have the potential to improve the therapeutic effect of colon cancer by recognizing the tumor vascular system through THPs. Additionally, the liposomes modified with BiP targeting peptides (WIFPWIQL) and dual-targeting liposomes modified with the NRG (GNGRG) and APRPG peptides inhibited colon tumor growth through the same mechanism.

Cellular penetrating peptides (CPPs) are a class of peptides capable of transporting large molecules and small particles across the cell membrane and into the cytoplasm. The transactivator of transcription (TAT) peptide is the first peptide discovered to possess such ability. Kuai et al developed a specialized TAT peptide liposome. It possessed a thiol-cleavable (like L-Cysteine) long PEG brush layer and a short, non-cleavable PEG layer with TAT peptide attached to it. The extended PEG brush layer functions as a powerful spatial barrier that reduces the opsonization and non-specific cellular interactions of TAT liposomes during passive accumulation. When TAT peptide liposomes passively accumulate inside the tumor, L-Cysteine is injected to cleave the long PEG layer and expose the cell-penetrating TAT peptide, promoting the absorption of liposomes by tumor cells. This design enables specific drug release in the TME and has been proven effective in a mouse subcutaneous C26 colon cancer model. Integrins are vital members of the cell adhesion molecule family. Functioning as transmembrane glycoproteins, they play a crucial role in the adhesion and signal transduction between cells and between cells and the ECM. They also regulate cellular functions including adhesion, migration, proliferation, and apoptosis. Integrin expression is notably upregulated in a range of solid tumors and their associated blood vessels, highlighting its crucial role in cancer progression and invasion.

The tripeptide sequence RGD, which is widely present in ECM proteins, can specifically bind to various integrins, making RGD peptides widely used as ligands targeting tumor cells. Liu et al constructed a cRGD peptide (Arg-Gly-Asp-d-Phe-Cys [RGDIC]-modified liposome that encapsulates matrine. In HT-29 colon cancer cell lines, this approach demonstrated an enhanced anti-proliferative effect, approximately two-fold greater, compared to free drugs. The PR_b-peptide (KSSPHSRNSGSGSGSGSRGDS) designed by the Kokkoli team binds the RGD motif with a synergistic PHSRN sequence, forming a fibronectin mimetic peptide specifically targets α5β1 integrins. PR_b-peptide liposomes can effectively target colon cancer cells and serve as carriers for various drugs, including DOX, 5-FU, and tumor necrosis factor-α.

While active targeting markedly enhances the specificity and therapeutic efficacy of nanomedicines, challenges such as ligand selection and rapid immune clearance in vivo need further investigation.
Stimulus-Responsive Targeting

Stimulus-responsive targeting is a sophisticated delivery strategy that utilizes NPs’ sensitivity to specific physical, chemical, and biological factors for precise drug release at the target site (Figure 6C). This approach involves constructing a Stimuli Response System (SRS) that rapidly and accurately responds to these stimuli by altering the composition and structure of nanocarriers. It addresses the current challenges such as slow drug release, low bioavailability, and suboptimal targeting. The triggers employed are broadly classified into endogenous and exogenous categories. Endogenous factors mainly refer to the characteristics of the TME, like low pH, tissue hypoxia, enzymatic activity, and redox status. Exogenous factors mainly include physical stimuli such as temperature, ultrasound, magnetic fields, and light, with pH-sensitive liposomes (PSL) and thermosensitive liposomes (TSL) being prime examples.

The tumor microenvironment (TME) in colorectal cancer is characterized by tissue hypoxia and low pH due to lactic acid production from tumor cell glycolysis. These characteristics contribute to cancer progression and chemoresistance through signaling pathways like hypoxia-inducible factor (HIF), presenting significant challenges for developing effective chemotherapy for colorectal cancer. The physical and chemical properties of pH-sensitive polymers, such as solubility, chain conformation, and surface activity, vary markedly with environmental pH. Drug delivery systems utilizing these polymers maintain stability in physiological environments but release their payload in acidic tumor settings, thus achieving tumor targeting. For instance, Juang et al developed pH-sensitive and peptide-modified LNPs to encapsulate the chemotherapy drug irinotecan and miR-200 which inhibits cancer cell metastasis. These NPs demonstrated pH-responsive release and enhanced cellular uptake driven by clathrin- and adsorptive-mediated endocytosis. They showed effective internalization and intracellular distribution in the acidic environment of the human colon cancer cell line HCT116, with their therapeutic effectiveness further confirmed in mouse models.

Thermosensitive liposomes are frequently employed as carriers for chemotherapy drugs, used in conjunction with local hyperthermia to trigger drug release and produce tumoricidal effects. Stimulus-responsive targeting strategies can be combined with active targeting modifications on the surface to further enhance drug targeting efficiency and increase cellular toxicity.

Applications of Lipid Nanoparticles (LNPs) in the Treatment of Colorectal Cancer

Colorectal cancer is a highly heterogeneous malignant tumor, making its effective treatment a significant challenge. LNPs have emerged as a versatile tool in this domain. They can encapsulate a diverse array of anti-tumor agents, including small molecules, peptides, proteins, and nucleic acids, offering selective targeting of cancer cells while sparing normal cells. Currently, researchers are actively exploring LNPs for targeted drug delivery, thermal therapy, and gene therapy specifically for colorectal cancer, showing promising potential in the field.

Lipid Nanoparticles (LNPs) for Traditional and Novel Drug Delivery in Colorectal Cancer Therapy

As research progresses, the efficacy of LNPs as carriers for various anti-tumor agents, including first-line drugs, biologics, and naturally derived anticancer compounds, has been increasingly validated in CRC therapy. Delivering drugs to the tumor sites using LNPs offers two major advantages: 1) LNPs can achieve comparable or superior therapeutic effects at lower drug doses compared to traditional formulations such as tablets, capsules, and liquids; 2) LNPs can enhance drug pharmacokinetics by minimizing systemic distribution, reducing toxicity, and decreasing the frequency of administration.

5-Fluorouracil (5-Fu), a uracil derivative classified as an antimetabolic antitumor drug, is among the most frequently utilized chemotherapeutics for CRC. However, its clinical application is constrained by poor selectivity, substantial toxic side effects, and an excessively brief plasma half-life. In response to these challenges, Patel et al encapsulated 5-FU in solid lipid nanoparticles, observing a concentration-dependent reduction in cell viability within Caco-2 human colorectal adenocarcinoma cell lines. Doxorubicin (DOX), another common chemotherapy drug with strong anti-cancer activity, faces limitations due to its cardiotoxicity and lack of tumor specificity. To address this, Zhang et al developed ginger-derived nanovectors (GDNVs), a nanocarrier
constructed from ginger lipids, capable of efficiently loading and targeting DOX delivery.\textsuperscript{156} Fluorescence imaging showed that GDNVs are internalized by tumor cells via the phagocytosis pathway with high efficiency. Udofo\textit{t} et al encapsulated 5-FU (pHLNps-5-FU) within PSL nanoparticles, which were further modified with anti-EGFR antibodies.\textsuperscript{157} Their evaluation in a subcutaneous tumor mouse model using the colon cancer cell line HCT-116 indicated a significant increase in tumor accumulation of pHLNps-5-FU, along with an extended plasma half-life. Irinotecan (IRI, CPT-11) is a second-line chemotherapeutic agent for advanced CRC that inhibits topoisomerase-1 to elicit anti-tumor activity. Bhaskaran et al prepared orally delivered IRI-loaded SLNs using cetyl palmitate via emulsification solvent evaporation and further modified them with chitosan.\textsuperscript{79} The surface-modified SLNs protect IRI from gastric acid, releasing only 3.33\% in an acidic environment within 2 hours. Furthermore, these drugs encapsulated in LNPs demonstrated enhanced anti-cancer activity compared to their free-form counterparts.

Beyond standard anti-tumor drugs, LNPs have demonstrated significant potential as an effective vehicle for the targeted delivery of diverse innovative therapeutics in CRC, offering unique advantages. Al-Asmari et al reported that liposomes containing scorpion toxin were more effective in combating cancer than the free form of the toxin in the human colorectal cancer cell line HCT-8.\textsuperscript{158} The in vitro release at pH 7.5 showed an initial rapid release of venom within the first 2 hours, followed by a plateau. Increased efficacy was evidenced by a lower survival rate in treated cells, a rise in reactive oxygen species (ROS) production, and a greater number of apoptotic cells. Furthermore, cell cycle analysis suggested a halt in the G0/G1 phase among these cells.

The evolving fields of metagenomics and metabolomics have illuminated the critical role of gut microbiota in the onset and progression of CRC, thereby attracting substantial research interest.\textsuperscript{159} Numerous studies have focused on developing LNP-based drugs targeting gut microbiota for CRC treatment. Omega-3 polyunsaturated fatty acids (PUFAs) show a significant association with gut microbiota and bile acid levels, with increased intake believed to reduce inflammation and strengthen anti-tumor immunity.\textsuperscript{160} The encapsulation of resveratrol in SLNs significantly enhanced the incorporation efficiency of \(\omega-3\) PUFAs in human HT-29 CRC cells and reduced tumor cell proliferation.\textsuperscript{161} Wu et al developed liposomes loaded with matairesinol, a compound exhibiting differential expression between healthy individuals and CRC patients, and found that they markedly improved CRC chemosensitivity by altering lipid metabolism.\textsuperscript{162} In both chemosensitive and drug-resistant CDX and PDX mouse models, matairesinol-liposomes notably increased the anti-cancer activity of 5-FU/calcium folinate combined with oxaliplatin (FOLFOX). Emerging strategies targeting gut microbiota and metabolic reprogramming through LNP technology offer promising directions and possibilities for the treatment of CRC.

**Enhanced Thermal Therapy Efficacy Using Lipid Nanoparticles in Colorectal Cancer**

LNPs exhibit robust capabilities in energy conversion and utilization, enabling them to produce thermal effects in response to various stimuli, including pH changes, ultrasound, magnetic fields, and light. This characteristic significantly enhances the efficacy of physical therapies. Superparamagnetic iron oxide nanoparticles (SPIONs), distinguished by their superparamagnetism, are extensively employed in medical applications, notably in magnetic resonance imaging (MRI) and magnetic hyperthermia.\textsuperscript{163} Shen et al developed folate-modified solid lipid nanoparticles (DFSLNs) encapsulating DOX and superparamagnetic iron oxide particles in pectin for colon-targeted delivery.\textsuperscript{116} This design combines chemotherapy and magnetic thermal ablation therapy. In addition to reducing cellular penetration through brush border membranes facilitated by proton-coupled FA transporters in the small intestine, DFSLNs also prolong retention time in the colon. Targeted LNPs boost the effectiveness of thermal therapy in cancer, especially when thermal therapy is aligned with other treatments.

**Nucleic Acid-Based Gene Therapy in Colorectal Cancer Utilizing Lipid Nanoparticles**

Gene therapy represents a promising avenue in cancer treatment, targeting pathogenic genes in a sequence-specific manner.\textsuperscript{164} This approach facilitates more precise and personalized anti-tumor therapy, underscoring its potential in oncological interventions. Gene therapy can be principally categorized into four types based on its potential mechanisms of action: (1) Gene addition or replacement, exemplified by mRNA encoding genes encapsulated in LNPs; (2) Regulation of gene expression, involving agents like miRNA, short-stranded small interfering RNA (siRNA), and long non-coding RNA (lncRNA); (3) Gene editing, utilizing tools such as Cas9 mRNA and single-guided RNA (sgRNA); and (4) DNA
or RNA-based vaccines.\textsuperscript{166} For gene therapy to be efficacious in vivo, it necessitates a delivery platform that is safe, effective, and stable. This platform must shield nucleic acids from degradation while facilitating cellular uptake and subsequent release of these acids. LNPs optimally satisfy the aforementioned requirements.

LNPs loaded with siRNA, mRNA, or DNA can modulate the expression of cancer-related genes, either by upregulating or downregulating them, thereby achieving therapeutic effects in the treatment of CRC (Table 2).

In CRC therapy, most LNP-based nucleic acid drugs focus on regulatory factors associated with cell proliferation, cell cycle, metastasis, and apoptosis, consequently inhibiting tumor growth. A noteworthy example involves the LNP-encapsulated siRNA targeting APRIL (A Proliferation-Inducing Ligand), a crucial regulator of cell proliferation. This ligand is characteristically overexpressed in colorectal cancer tissues, where it stimulates the growth of tumor cells. Silencing APRIL has been demonstrated to effectively control tumor progression.\textsuperscript{180} Analogously, the siRNA-mediated knockdown of DNA-bind-2 inhibitors (Id2) or cDNA overexpression of FAS has been observed to curb tumor cell proliferation and reduce tumor burden in mice.\textsuperscript{170,178} Additionally, cell cycle-related targets include the E2F1 transcription factor and PCTAIRE1 (also known as PCTK1 or Cyclin Dependent Kinase 16 [Cdk16]).\textsuperscript{173,174}

To enhance anti-tumor efficacy, recent studies have extensively employed LNP siRNA to target and reshape the tumor microenvironment. Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-degrading metabolic enzyme that is overexpressed in tumor-draining lymph nodes (TDLNs) and tumor tissues.\textsuperscript{181} This enzyme catalyzes the degradation of the essential amino acid tryptophan (TRP) into kynurenine (KYN), a process that directly activates regulatory T cells (Tregs) while simultaneously inducing the inactivation of cytotoxic T lymphocytes (CTL).\textsuperscript{182–184} This activity is crucial in establishing an immunosuppressive tumor microenvironment (ITM). Targeting IDO1 with siRNA has shown promise in improving immunotherapy outcomes. In a nude mouse subcutaneous tumor model using human colorectal cancer cells, the combined administration of oxaliplatin (OXA) and CLANsiIDO1 enhanced dendritic cell maturation, increased tumor-infiltrating T lymphocytes, and decreased regulatory T cells, thereby reversing IDO1-mediated immunosuppression.\textsuperscript{167} Moreover, there is a close interaction between the NF-κB signaling pathway and the tumor microenvironment.\textsuperscript{185} Zou et al found that using CD DTX.siRelA.PEG-FA nanoparticles to downregulate the NF-κB subunit RelA enhanced docetaxel’s apoptotic effects and inhibited tumor growth in mice.\textsuperscript{175} Specifically, the coformulation exhibited pH-triggered release, with higher release in acidic environments. Upon entering the endosome (pH ≈ 5.5 to 6.0), it enabled the simultaneous release of DTX and siRNA into the cytoplasm, leading to a synergistic apoptotic effect. Additionally, factors like COX-2 and abnormal fatty acid metabolism, pivotal in the tumor microenvironment, have been targeted.\textsuperscript{166,187} Xu et al introduced EpCAM aptamers into 3WJ pRNA nanoparticles, enabling targeted delivery of Delta-5 desaturase (D5D) siRNA to human colon cancer HCA-7 cells.\textsuperscript{188} In mice bearing HCA-7 tumors, the administered nanoparticles facilitated a synergistic effect with γ-linolenic acid (DGLA). This combination promoted COX-2-catalyzed peroxidation of DGLA and the formation of 8-HOA, leading to the inhibition of histone deacetylases (HDAC) activity. This process effectively regulated the acetylation state of histones, induced apoptosis in tumor cells, and exhibited significant anti-tumor effects.

Finally, LNP siRNA delivery has also been employed to overcome the challenge of cancer drug resistance and restore tumor sensitivity to anticancer agents. A key player in chemotherapy sensitivity is the multidrug resistance gene 1 (MDR1), which regulates drug efflux through its encoded P-glycoprotein. This protein actively transports drugs out of cells, reducing intracellular drug concentrations and consequently leading to resistance. Research has shown that silencing MDR1 can significantly enhance the efficacy of paclitaxel, outperforming monotherapy approaches.\textsuperscript{172} Likewise, Zhiani et al demonstrated that the concurrent application of integrin-β1 siRNA/HNP and Regorafenib/HNP effectively downregulated integrin-β1 gene expression.\textsuperscript{176} This downregulation triggered apoptosis in drug-resistant cell lines and reinstated tumor cell sensitivity to the receptor tyrosine kinase inhibitor (RTKI) Regorafenib.\textsuperscript{189}

mRNA therapy directly exerts anti-tumor effects through the delivery of mRNA-encoded functional proteins. Wu et al encapsulated ALKBH5 mRNA within folate-modified exosome liposome hybrid nanoparticles for application in patient-derived xenograft (PDX) model mice.\textsuperscript{177} Consequently, the ALKBH5 mRNA nanotherapeutic markedly suppressed colorectal tumor development in treated mice, which was attributed to the modulation of the ALKBH5/JMJD8/PKM2 axis and the inhibition of glycolysis. Golubovskaya et al employed LNP to deliver EpCAM-CD3 bispecific antibodies, encapsulating EpCAM-CD3-hFc mRNA-LNP.\textsuperscript{190} EpCAM (Epithelial Cell Adhesion Molecule) is a prevalent antigen on
<table>
<thead>
<tr>
<th>Payload</th>
<th>Gene Target/Product</th>
<th>LNP Category</th>
<th>Administration Route</th>
<th>Model</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene silencing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>siRNA</td>
<td>Indoleamine 2,3-dioxygenase-1 (IDO1)</td>
<td>Cationic lipid-assisted nanoparticles (CLANs)</td>
<td>Intravenous injection</td>
<td>Subcutaneous colorectal tumor model</td>
<td>[167]</td>
</tr>
<tr>
<td>siRNA</td>
<td>Hypoxia inducible factor 1α (HIF-1α)</td>
<td>RGD-targeted multifunctional lipid ECO/siHIF-1α nanoparticles</td>
<td>Intravenous injection</td>
<td>Mouse HT29 colon cancer model</td>
<td>[168]</td>
</tr>
<tr>
<td>siRNA</td>
<td>A proliferation-inducing ligand (APRIL)</td>
<td>Negative lipidoid nanoparticles (NLNs)</td>
<td>Enema delivery</td>
<td>CRC animal models</td>
<td>[169]</td>
</tr>
<tr>
<td>siRNA</td>
<td>Inhibitor of DNA-bind-2 (Id2)</td>
<td>Neutral liposome 1,2-dioleyl-sglycer-3-phosphatidyliccholine</td>
<td>Intrapertioneal administration</td>
<td>CRC animal models (CT-26)</td>
<td>[170]</td>
</tr>
<tr>
<td>siRNA</td>
<td>Survivin</td>
<td>Nanoliposomes</td>
<td>Transfection</td>
<td>LoVo cells</td>
<td>[171]</td>
</tr>
<tr>
<td>siRNA</td>
<td>Multidrug resistance gene (MDR1)</td>
<td>A carrier composed of a cationic oligomer (PEI(1200)), a hydrophilic polymer (polyethylene glycol) and a biodegradable lipid-based crosslinking moiety</td>
<td>Transfection</td>
<td>Human colon CSCs (CD133+ enriched cell population)</td>
<td>[172]</td>
</tr>
<tr>
<td>siRNA</td>
<td>E2F1</td>
<td>Nanoliposomes</td>
<td>Transfection</td>
<td>Cultured colon carcinoma cells and cultured human biopsy of colonic mucosa</td>
<td>[173]</td>
</tr>
<tr>
<td>siRNA</td>
<td>PCTAIRE1</td>
<td>Lipid nanoparticles</td>
<td>Intratumor injection</td>
<td>Mouse HCT116 subcutaneous tumor models</td>
<td>[174]</td>
</tr>
<tr>
<td>siRNA</td>
<td>RelA</td>
<td>An amphiphilic cation cyclodextrin (CD) nanoparticle modified with PEGylated folate</td>
<td>Intravenous injection</td>
<td>Mouse CT26 subcutaneous tumor models</td>
<td>[175]</td>
</tr>
<tr>
<td>siRNA</td>
<td>Integrin-β1</td>
<td>Dimethyldioctadecylammonium bromide (DDAB)-methoxy poly (ethylene glycol) (mPEG)-poly-ε-caprolactone (PCL) hybrid nanoparticles (HNPs)</td>
<td>Transfection</td>
<td>Regorafenib-resistant human colon cancer cell line (SW-48)</td>
<td>[176]</td>
</tr>
<tr>
<td>Gene expression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA</td>
<td>ALKBH5</td>
<td>Exosome-liposome hybrid nanoparticles</td>
<td>Intratumor injection</td>
<td>Mouse preclinical tumor models</td>
<td>[177]</td>
</tr>
<tr>
<td>cDNA</td>
<td>FAS</td>
<td>Cationic lipid nanoparticle DOTAP-Cholesterol</td>
<td>Intravenous injection</td>
<td>Mouse CT26 subcutaneous tumor models</td>
<td>[178]</td>
</tr>
<tr>
<td>Gene editing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgRNA</td>
<td>KRAS</td>
<td>Nanoliposomal (NL) particle</td>
<td>Intravenous injection</td>
<td>Mice with KRAS-mutated CRC</td>
<td>[179]</td>
</tr>
<tr>
<td>mRNA</td>
<td>Cas9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
the surface of epithelial malignant tumor cells. The mRNA-encoded dual antibody specifically targets the EpCAM antigen on one end, while concurrently bridging T cells via the CD3 antibody on the other, thereby activating T cells to eradicate EpCAM-positive Lovo cells. This approach not only selectively eliminates tumor cells but also escalates IFN-γ secretion from T cells in a dose-dependent manner. Recently, da Silva et al developed an LNP platform via microfluidic mixing to deliver tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mRNA to the tumor microenvironment (TME). Combined with TME normalization, this platform effectively induced apoptosis in colon cancer cells. This work highlights the promising potential of LNP-mRNA therapeutics in solid tumor immunotherapy.

RNA vaccines function by introducing tumor antigen RNA into the body, thereby eliciting an immune response aimed at combating cancer. A critical challenge for this strategy is the safe and efficient delivery of RNA to the target site while minimizing RNA degradation. In response to this challenge, numerous researchers have turned to LNPs as a solution. To effectively induce anti-tumor immunity, Dai et al refined the synthesis of tumor RNA liposome-polycationic DNA complex (LPD) nanoliposomes vaccines, enhancing the total RNA encapsulation capacity for use in a CT-26 colorectal cancer mouse model (Figure 7A and B). Their results demonstrated that these nanoparticles could activate dendritic cells (DCs) and T cells, significantly impede tumor growth, and exhibit minimal toxicity to normal organs (Figure 7C). Additionally, Pam2Cys, a synthetic neutral fatty acid, known for its ability to activate the Toll-like receptor (TLR) 2/6 pathway, has been recognized for its potential to trigger both humoral and cellular adaptive immune responses. Gu et al developed an innovative antigen mRNA-LNP vaccine incorporating Pam2Cys. This vaccine delayed tumor progression and markedly improved survival rates. In the CT26 colon cancer mouse model, it was observed that this novel vaccine eradicated existing tumors in 10% of the subjects. Therefore, LNPs hold significant potential in gene therapy for CRC, particularly in terms of targeting tumors and enhancing immune responses.

Figure 7 Schematic illustration of RNA-based LPD nanoliposome vaccines. (A) The stepwise preparation of the nanoparticles. (B) The components of LPD nanoliposomes. (C) The schematic diagram of LPD nanoliposomes’ effect on DC maturation and T cell activation. In combination with oxaliplatin, the vaccines induce activation of CD8+ T cells and exert anti-tumor effects. Created with BioRender.com.
Conclusion and Perspectives

Lipid-based nanoparticles, particularly SLNs, NLCs, and PLNs, are emerging as a promising platform for CRC therapy. Their attributes include biodegradability, biocompatibility, reduced toxicity, and customizable functionality. LNPs designed for CRC treatment can be administered through various routes, including oral, rectal, intravenous, intratumoral injection, hepatic artery infusion, and intraperitoneal administration. Optimized carrier formulations, appropriate targeting strategies, and suitable administration routes improve the pharmacokinetic and pharmacodynamic properties of LNPs, thereby enhancing their targeted anti-tumor effects. Noteworthy progress has been made with some of these platforms, indicating a bright future for this technology. This article reviews recent published examples of LNPs as nanocarriers for the treatment of colorectal cancer. A wide range of drugs for CRC treatment, including traditional chemotherapy agents, novel anti-cancer drugs, magnetic hyperthermia particles, and nucleic acid medications, have been successfully incorporated into LNPs. These strategies have shown promising results in tumor targeting and anti-tumor efficacy in colorectal cancer models, both in vivo and in vitro. This smart nanoplatform also allows for the loading of various antitumor agents, particularly the combination of novel and traditional drugs, to trigger a potent antitumor response in patients resistant to conventional therapeutic regimens.

Despite rapid advancements in LNPs for cancer therapy, their clinical application still faces obstacles: (1) Industrial scale-up. The complexity of LNP formulation and preparation, characterized by multi-step reactions, leads to inconsistent repeatability, posing a significant challenge for industrial-scale manufacturing. (2) Tumor microenvironment complexity: Current in vitro and in vivo models inadequately mimic the human tumor microenvironment, resulting in less effective clinical outcomes than anticipated. Optimizing LNP formulations and gaining a deeper understanding of the factors influencing their biological distribution are crucial for enhancing treatment efficacy. For instance, adjuvant lipids in mRNA-LNP vaccines have been adopted to improve adaptive immune responses.195 A thorough mechanistic exploration of the structure-activity relationship between various ionizable lipids and LNP distribution in specific organs or cells is also needed. (3) Biocompatibility. Concerns regarding the immunogenicity and toxicity of LNPs still exist. The immune response can accelerate the clearance of LNPs and even lead to serious complications such as hemolysis and thrombosis.196 Lipid components affect the immunogenicity of LNPs, as evidenced by the upregulation differences of various cytokines in LNPs with different ionizable lipids (eg, SM-102 and ALC-0315).197 PEG lipids may trigger PEG antibodies that cause severe hypersensitivity reactions.198,199 Replacing PEG lipids with poly sarcosine lipids (pSar) may address these issues.197 Currently, the toxicity assessment of nanoparticles (NPs) is not fully developed. Unstable NPs may form micrometer-sized aggregates, block capillary beds, and lead to serious complications.200 Injection of LNPs may cause liver or spleen damage and interfere with fatty acid and lipid metabolism.201 Future research should focus on addressing these challenges to fully realize the potential of LNP-based therapies for CRC. This includes developing scalable production methods, understanding and manipulating the tumor microenvironment, improving biocompatibility, and conducting comprehensive long-term safety studies.

In summary, despite some limitations, further research is imperative to refine therapeutic LNPs for CRC treatment, considering the increasing global burden of CRC.202 Progress in this area is vital for the clinical translation of LNPs and for advancing colorectal cancer therapy.

Acknowledgments

We would like to thank the Zhejiang Provincial Natural Science Foundation of China for funding this research work with the project number “LHDMZ23H160003”.

Disclosure

The authors report no conflicts of interest in this work.

References


141. Pangburn TO, Bates FS, Kokkoli E. Polyionomes functionalized via “click” chemistry with the fibronectin mimetic peptides PR_b and GRGDSP for targeted delivery to cells with different levels of αβ1 expression. Soft Matter. 2012;8(16):4449–4461. doi:10.1039/c2sm06922a


